AbbVie has filed risankizumab in the US seeking approval for its use to treat moderate-to-severe plaque psoriasis.

The submission is supported by four Phase III studies involving more than 2,000 patients with the condition, and data showing that more than half of patients receiving the drug achieved complete skin clearance (PASI 100) at one year.

"The risankizumab submission represents an important milestone in our goal of advancing treatment for people living with immune-mediated diseases," said Michael Severino, executive vice president, research and development and chief scientific officer, AbbVie.

"Risankizumab has the potential to be an important treatment option for people living with plaque psoriasis and we look forward to working with the FDA throughout the review process."

Risankizumab is an experimental IL-23 inhibitor to which AbbVie bought rights to from Boehringer Ingelheim in 2015.

The drug is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing.

Its potential is also being investigated in other immunological disorders, such as Crohn’s disease, psoriatic arthritis and asthma.